Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives $15.97 Consensus Target Price from Analysts

Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) have received an average rating of “Buy” from the nine analysts that are currently covering the firm, MarketBeat Ratings reports. Eight research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $15.97.

A number of brokerages have recently commented on VYGR. Canaccord Genuity Group reiterated a “buy” rating and set a $14.00 price objective on shares of Voyager Therapeutics in a research report on Thursday, November 14th. StockNews.com downgraded Voyager Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, December 13th. HC Wainwright reissued a “buy” rating and issued a $30.00 price target on shares of Voyager Therapeutics in a research note on Thursday, November 14th. Wedbush initiated coverage on Voyager Therapeutics in a report on Friday, November 29th. They set an “outperform” rating and a $11.00 price objective on the stock. Finally, Citigroup initiated coverage on shares of Voyager Therapeutics in a report on Monday, December 2nd. They issued a “buy” rating and a $12.00 target price for the company.

Insider Buying and Selling at Voyager Therapeutics

In other news, COO Robin Swartz sold 6,500 shares of the business’s stock in a transaction on Monday, December 23rd. The shares were sold at an average price of $5.65, for a total value of $36,725.00. Following the completion of the sale, the chief operating officer now directly owns 112,328 shares in the company, valued at approximately $634,653.20. The trade was a 5.47 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 4.53% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Victory Capital Management Inc. grew its stake in shares of Voyager Therapeutics by 14.5% in the second quarter. Victory Capital Management Inc. now owns 12,892 shares of the company’s stock worth $102,000 after acquiring an additional 1,630 shares during the last quarter. Hunter Perkins Capital Management LLC grew its position in Voyager Therapeutics by 3.3% in the 3rd quarter. Hunter Perkins Capital Management LLC now owns 64,040 shares of the company’s stock worth $375,000 after purchasing an additional 2,025 shares during the last quarter. Empowered Funds LLC increased its holdings in shares of Voyager Therapeutics by 5.4% during the 3rd quarter. Empowered Funds LLC now owns 44,809 shares of the company’s stock worth $262,000 after purchasing an additional 2,278 shares during the period. Federated Hermes Inc. raised its position in shares of Voyager Therapeutics by 0.5% during the second quarter. Federated Hermes Inc. now owns 554,214 shares of the company’s stock valued at $4,384,000 after buying an additional 2,638 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its stake in shares of Voyager Therapeutics by 2.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 137,477 shares of the company’s stock valued at $804,000 after buying an additional 3,473 shares during the period. Institutional investors own 48.03% of the company’s stock.

Voyager Therapeutics Price Performance

VYGR opened at $5.28 on Friday. The business has a 50 day moving average price of $6.09 and a two-hundred day moving average price of $6.80. The company has a market capitalization of $288.43 million, a price-to-earnings ratio of 7.44 and a beta of 0.93. Voyager Therapeutics has a 1-year low of $5.14 and a 1-year high of $10.66.

Voyager Therapeutics (NASDAQ:VYGR) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.29. The company had revenue of $24.63 million during the quarter, compared to the consensus estimate of $12.63 million. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. During the same period in the prior year, the company earned ($0.59) EPS. Equities analysts expect that Voyager Therapeutics will post -0.89 EPS for the current fiscal year.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.